All the Active Ingredient Drugs
LMWH. Enoxaparin (as sodium) 100 mg/ml. PRE-FILLED SYR.: 2 x 20 mg/0.2 ml,
40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8
ml, 100 mg/1.0 ml.
SC admin./IV bolus during
hemodialysis.
Dosage must be individ. adjust. by
phys. accord. medic. condit. of the pt.
See lit.
At doses of 20 mg, 40 mg: Proph. tmt. of
thrombo-emb. disord. of venous orig.,
partic. in orthop. surg. or in general surg.
Preven. of thrombus format. in the extracorporeal
circul. during hemodialysis.
At dose of 40 mg: Proph. tmt. of DVT in
pts. who are bedridden due to an acute
med. disord., Heart fail. (HYHA class III or
IV), Acute resp. fail., Episode of acute
infec., acute rheum. disord, comb. with at
least one other ven. thromboemb. risk fac.
At doses of 60, 80 ,100 mg: Tmt. of DVT,
unst. angina and non-Q-wave MI
adminis. concur. with aspirin. Tmt. of
pulmonary embolism., Tmt. of acute STseg.
elevation MI , in comb. with a
thrombolytic ag. in pts. eligible or not for
subseq. coron. angioplas.
C/I: Curative Or Preventive: Hypersens.
to enoxaparin, heparin or derive. incl.
other LMWH; Hist. of serious type II HIT;
Bleed. or tendency to bleed related to
impair. hemostasis; Organ. lesion likely
to bleed; Clinic. signif. active bleed.;
Curative Doses: Intracerebr. hemorrh.;
Spinal or epid. anesth. must never be
performed in pts under curative LMWH
tmt.
LMWH. Enoxaparin (as sodium) 2000 IU, 4000 IU, 6000 IU, 8000 IU, 10000IU. PREFILL.SYR. (sol. for inj.): 2,6,10,20,50 × 2,000 IU (20 mg)/0.2 mL; 2,6,10,20,30,50 × 4,000 IU (40 mg)/0.4 mL; 2,6,10,12,24, 30 × 6,000 IU (60 mg)/0.6 mL, 8,000 IU (80 mg)/0.8mL, 10,000 IU (100 mg)/1 mL.
Dosage must be individ. adjust. by phys. accord. medic. condit. of the pt. See lit.
Prophylaxis of VTE in moder. & high risk surgical patients, in particular those undergoing orthopaedic or general surgery includ. cancer surg.
Prophylaxis of venous thromboembol. dis. in medical pts. with an acute illness (such as acute heart failure, respirat. insufficiency, severe infec. or rheumatic dis.) and reduced mobility at increased risk of venous thromboemb.
Tmt. of DVT and PE, exclud. PE likely to require thrombolytic ther. or surgery. Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Acute coronary syndr.:
- Tmt. of unstable angina and Non ST-segment elevation MI (NSTEMI), in comb. with oral acetylsalicylic acid.
- Tmt. of acute ST-segment elevation myocardial infarction (STEMI) include. pts. to be managed medically or with subsequent percutan. coronary intervent. (PCI).
C/I: Hypersens. enoxaparin sodium, heparin or its derivate., includ. other LMWH.
History of immune mediated heparin-induced thrombocytop. (HIT) within the past 100 days or in the presence of circulat. antibodies.
Active clinically significant bleed., conditions with a high risk of hemorrhage, includ. recent haemorrhagic stroke, GI ulcer, presence of malignant neoplasm at high risk of bleed., recent brain, spinal or ophthalmic surg. , known or suspected oesophageal varices, arteriovenous malformat., vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities; Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for tmt. in the previous 24 hrs.